Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132777524> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2132777524 endingPage "37" @default.
- W2132777524 startingPage "32" @default.
- W2132777524 abstract "Imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ; Glivec, Novartis Pharma AG, Basel, Switzerland), a signal transduction inhibitor with preferential effects against the tyrosine kinase activity of the protein product of the ABL proto-oncogene, induced hematologic responses in ≥90% of patients with chronic-phase chronic myeloid leukemia (CML). In Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), the BCR-ABL translocation is the main transforming event, making it another hematologic malignancy targeted by this ABL-tyrosine kinase inhibitor. In an international multicenter phase II trial, imatinib-induced hematologic responses (typically brief) were achieved in 60% of patients with relapsed or refractory Ph+ ALL. Subsequently, the German Multicenter Study Group for Adult ALL (GMALL) analyzed 59 patients treated in two successive nonrandomized phase II trials of imatinib in patients with relapsed or refractory Ph+ ALL. Peripheral blood blasts cell clearance occurred within 8 to 14 days in most patients. However, in a significant proportion, blast counts subsequently increased 16 to 50 days after treatment onset. Imatinib mesylate was particularly effective in patients with relapse after stem cell transplantation (SCT); 75% of patients achieved complete leukemic response. Rapid development of resistance during treatment with imatinib mesylate remains a major problem. Further research efforts should explore the mechanisms of resistance to imatinib mesylate; effectiveness of other targeted therapies (eg, farnesyl transferase inhibitors [FTIs]); combination therapies; and inclusion of strategies for immune response modification (eg, donor lymphocyte infusions, interferon-α) for Ph/BCR-ABL–positive leukemias. Semin Hematol 39(suppl 3):32-37. Copyright 2002, Elsevier Science (USA). All rights reserved." @default.
- W2132777524 created "2016-06-24" @default.
- W2132777524 creator A5051371787 @default.
- W2132777524 creator A5066213019 @default.
- W2132777524 creator A5067318724 @default.
- W2132777524 date "2002-10-01" @default.
- W2132777524 modified "2023-09-25" @default.
- W2132777524 title "Targeted therapies in the treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia" @default.
- W2132777524 cites W1514944406 @default.
- W2132777524 cites W1558827591 @default.
- W2132777524 cites W1965295262 @default.
- W2132777524 cites W1965956395 @default.
- W2132777524 cites W1972804480 @default.
- W2132777524 cites W1996254906 @default.
- W2132777524 cites W2006518962 @default.
- W2132777524 cites W2076372887 @default.
- W2132777524 cites W2131067167 @default.
- W2132777524 cites W2142969636 @default.
- W2132777524 cites W2171722798 @default.
- W2132777524 cites W2263837564 @default.
- W2132777524 cites W2312804644 @default.
- W2132777524 cites W2329648702 @default.
- W2132777524 cites W4231364676 @default.
- W2132777524 doi "https://doi.org/10.1053/shem.2002.36927" @default.
- W2132777524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12447850" @default.
- W2132777524 hasPublicationYear "2002" @default.
- W2132777524 type Work @default.
- W2132777524 sameAs 2132777524 @default.
- W2132777524 citedByCount "26" @default.
- W2132777524 countsByYear W21327775242014 @default.
- W2132777524 countsByYear W21327775242015 @default.
- W2132777524 countsByYear W21327775242017 @default.
- W2132777524 countsByYear W21327775242018 @default.
- W2132777524 countsByYear W21327775242020 @default.
- W2132777524 countsByYear W21327775242021 @default.
- W2132777524 crossrefType "journal-article" @default.
- W2132777524 hasAuthorship W2132777524A5051371787 @default.
- W2132777524 hasAuthorship W2132777524A5066213019 @default.
- W2132777524 hasAuthorship W2132777524A5067318724 @default.
- W2132777524 hasConcept C104317684 @default.
- W2132777524 hasConcept C121608353 @default.
- W2132777524 hasConcept C126322002 @default.
- W2132777524 hasConcept C138626823 @default.
- W2132777524 hasConcept C143998085 @default.
- W2132777524 hasConcept C203014093 @default.
- W2132777524 hasConcept C2777583451 @default.
- W2132777524 hasConcept C2778729363 @default.
- W2132777524 hasConcept C2778820342 @default.
- W2132777524 hasConcept C2778904597 @default.
- W2132777524 hasConcept C2911091166 @default.
- W2132777524 hasConcept C3019892230 @default.
- W2132777524 hasConcept C55493867 @default.
- W2132777524 hasConcept C71924100 @default.
- W2132777524 hasConcept C86803240 @default.
- W2132777524 hasConcept C98274493 @default.
- W2132777524 hasConceptScore W2132777524C104317684 @default.
- W2132777524 hasConceptScore W2132777524C121608353 @default.
- W2132777524 hasConceptScore W2132777524C126322002 @default.
- W2132777524 hasConceptScore W2132777524C138626823 @default.
- W2132777524 hasConceptScore W2132777524C143998085 @default.
- W2132777524 hasConceptScore W2132777524C203014093 @default.
- W2132777524 hasConceptScore W2132777524C2777583451 @default.
- W2132777524 hasConceptScore W2132777524C2778729363 @default.
- W2132777524 hasConceptScore W2132777524C2778820342 @default.
- W2132777524 hasConceptScore W2132777524C2778904597 @default.
- W2132777524 hasConceptScore W2132777524C2911091166 @default.
- W2132777524 hasConceptScore W2132777524C3019892230 @default.
- W2132777524 hasConceptScore W2132777524C55493867 @default.
- W2132777524 hasConceptScore W2132777524C71924100 @default.
- W2132777524 hasConceptScore W2132777524C86803240 @default.
- W2132777524 hasConceptScore W2132777524C98274493 @default.
- W2132777524 hasIssue "4" @default.
- W2132777524 hasLocation W21327775241 @default.
- W2132777524 hasLocation W21327775242 @default.
- W2132777524 hasOpenAccess W2132777524 @default.
- W2132777524 hasPrimaryLocation W21327775241 @default.
- W2132777524 hasRelatedWork W1508329619 @default.
- W2132777524 hasRelatedWork W1970420999 @default.
- W2132777524 hasRelatedWork W2019199342 @default.
- W2132777524 hasRelatedWork W2073439508 @default.
- W2132777524 hasRelatedWork W2156238761 @default.
- W2132777524 hasRelatedWork W2396472562 @default.
- W2132777524 hasRelatedWork W2415374392 @default.
- W2132777524 hasRelatedWork W2775730895 @default.
- W2132777524 hasRelatedWork W3189565403 @default.
- W2132777524 hasRelatedWork W2187195062 @default.
- W2132777524 hasVolume "39" @default.
- W2132777524 isParatext "false" @default.
- W2132777524 isRetracted "false" @default.
- W2132777524 magId "2132777524" @default.
- W2132777524 workType "article" @default.